Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
In a phase 2 trial involving 166 patients with moderate-to-severe plaque psoriasis, risankizumab, a humanized monoclonal antibody that selectively inhibits IL-23, achieved clinical response superior to that achieved with ustekinumab, an IL-12 and IL-23 inhibitor. Psoriasis is a chronic immune-mediat...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2017-04, Vol.376 (16), p.1551-1560 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1560 |
|---|---|
| container_issue | 16 |
| container_start_page | 1551 |
| container_title | The New England journal of medicine |
| container_volume | 376 |
| creator | Papp, Kim A Blauvelt, Andrew Bukhalo, Michael Gooderham, Melinda Krueger, James Lacour, Jean-Philippe Menter, Alan Philipp, Sandra Sofen, Howard Tyring, Stephen Berner, Beate R Visvanathan, Sudha Pamulapati, Chandrasena Bennett, Nathan Flack, Mary Scholl, Paul Padula, Steven J |
| description | In a phase 2 trial involving 166 patients with moderate-to-severe plaque psoriasis, risankizumab, a humanized monoclonal antibody that selectively inhibits IL-23, achieved clinical response superior to that achieved with ustekinumab, an IL-12 and IL-23 inhibitor.
Psoriasis is a chronic immune-mediated inflammatory skin disease that occurs in 2% of adults; it has a substantial effect on quality of life and is associated with obesity, hypertension, diabetes mellitus, hypercholesterolemia, and the metabolic syndrome.
1
–
4
The proinflammatory cytokine interleukin-23 is thought to play a pivotal role in the pathogenesis of psoriasis by inducing and maintaining T helper (Th) 17 cells, Th22 cells, innate lymphoid cells, and the effector cytokines interleukin-17, interleukin-22, and tumor necrosis factor (TNF) α.
5
–
9
Interleukin-23 is composed of two subunits, p19 and p40. The p19 subunit is unique to interleukin-23, whereas the p40 subunit . . . |
| doi_str_mv | 10.1056/NEJMoa1607017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1891089845</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4321886127</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-c2b37670b4d3f5f2f9854d125212361a83edde6914e1c56625b47b2a9fe37e633</originalsourceid><addsrcrecordid>eNp10E1Lw0AQBuBFFFurR68SEMHL6n4ne5RSq9KqqD2HTTKBtE227iaC_nq3tgoKzmVgeHgZXoSOKbmgRKrL-9Hd1BqqSExovIP6VHKOhSBqF_UJYQkWseY9dOD9nIShQu-jHksE45zQPho_Vd40i-qjq00WvYHznY9mvoVF1XydSuuiqS3AmRZwa_EzBATR49K8dmF56yrjK3-I9kqz9HC03QM0ux69DG_w5GF8O7ya4Jxr0uKcZTxWMclEwUtZslInUhSUSUYZV9QkHIoClKYCaC6VYjITccaMLoHHoDgfoPNN7srZ8IBv07ryOSyXpgHb-ZQmmpJEJ0IGevqHzm3nmvDdWhHGhVQkKLxRubPeOyjTlatq495TStJ1w-mvhoM_2aZ2WQ3Fj_6uNICzDahrnzYwr_8J-gS-oIBZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1890234560</pqid></control><display><type>article</type><title>Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis</title><source>MEDLINE</source><source>Free E-Journal (出版社公開部分のみ）</source><source>New England Journal of Medicine</source><creator>Papp, Kim A ; Blauvelt, Andrew ; Bukhalo, Michael ; Gooderham, Melinda ; Krueger, James ; Lacour, Jean-Philippe ; Menter, Alan ; Philipp, Sandra ; Sofen, Howard ; Tyring, Stephen ; Berner, Beate R ; Visvanathan, Sudha ; Pamulapati, Chandrasena ; Bennett, Nathan ; Flack, Mary ; Scholl, Paul ; Padula, Steven J</creator><creatorcontrib>Papp, Kim A ; Blauvelt, Andrew ; Bukhalo, Michael ; Gooderham, Melinda ; Krueger, James ; Lacour, Jean-Philippe ; Menter, Alan ; Philipp, Sandra ; Sofen, Howard ; Tyring, Stephen ; Berner, Beate R ; Visvanathan, Sudha ; Pamulapati, Chandrasena ; Bennett, Nathan ; Flack, Mary ; Scholl, Paul ; Padula, Steven J</creatorcontrib><description>In a phase 2 trial involving 166 patients with moderate-to-severe plaque psoriasis, risankizumab, a humanized monoclonal antibody that selectively inhibits IL-23, achieved clinical response superior to that achieved with ustekinumab, an IL-12 and IL-23 inhibitor.
Psoriasis is a chronic immune-mediated inflammatory skin disease that occurs in 2% of adults; it has a substantial effect on quality of life and is associated with obesity, hypertension, diabetes mellitus, hypercholesterolemia, and the metabolic syndrome.
1
–
4
The proinflammatory cytokine interleukin-23 is thought to play a pivotal role in the pathogenesis of psoriasis by inducing and maintaining T helper (Th) 17 cells, Th22 cells, innate lymphoid cells, and the effector cytokines interleukin-17, interleukin-22, and tumor necrosis factor (TNF) α.
5
–
9
Interleukin-23 is composed of two subunits, p19 and p40. The p19 subunit is unique to interleukin-23, whereas the p40 subunit . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1607017</identifier><identifier>PMID: 28423301</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adult ; Aged ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Basal cell carcinoma ; Body weight ; Carcinoma ; Cytokines ; Dermatologic Agents - adverse effects ; Dermatologic Agents - therapeutic use ; Double-Blind Method ; Drug dosages ; FDA approval ; Female ; Humans ; Immunoglobulin G ; Immunotherapy ; Interleukin 12 ; Interleukin 23 ; Interleukin-12 - antagonists & inhibitors ; Interleukin-23 - antagonists & inhibitors ; Kaplan-Meier Estimate ; Light therapy ; Male ; Middle Aged ; Monoclonal antibodies ; Pharmaceutical industry ; Psoriasis ; Psoriasis - classification ; Psoriasis - drug therapy ; Scalp - pathology ; Severity of Illness Index ; Skin ; Skin cancer ; TNF inhibitors ; Tumor necrosis factor-TNF ; Ustekinumab - adverse effects ; Ustekinumab - therapeutic use</subject><ispartof>The New England journal of medicine, 2017-04, Vol.376 (16), p.1551-1560</ispartof><rights>Copyright © 2017 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-c2b37670b4d3f5f2f9854d125212361a83edde6914e1c56625b47b2a9fe37e633</citedby><cites>FETCH-LOGICAL-c390t-c2b37670b4d3f5f2f9854d125212361a83edde6914e1c56625b47b2a9fe37e633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1607017$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa1607017$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28423301$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Papp, Kim A</creatorcontrib><creatorcontrib>Blauvelt, Andrew</creatorcontrib><creatorcontrib>Bukhalo, Michael</creatorcontrib><creatorcontrib>Gooderham, Melinda</creatorcontrib><creatorcontrib>Krueger, James</creatorcontrib><creatorcontrib>Lacour, Jean-Philippe</creatorcontrib><creatorcontrib>Menter, Alan</creatorcontrib><creatorcontrib>Philipp, Sandra</creatorcontrib><creatorcontrib>Sofen, Howard</creatorcontrib><creatorcontrib>Tyring, Stephen</creatorcontrib><creatorcontrib>Berner, Beate R</creatorcontrib><creatorcontrib>Visvanathan, Sudha</creatorcontrib><creatorcontrib>Pamulapati, Chandrasena</creatorcontrib><creatorcontrib>Bennett, Nathan</creatorcontrib><creatorcontrib>Flack, Mary</creatorcontrib><creatorcontrib>Scholl, Paul</creatorcontrib><creatorcontrib>Padula, Steven J</creatorcontrib><title>Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In a phase 2 trial involving 166 patients with moderate-to-severe plaque psoriasis, risankizumab, a humanized monoclonal antibody that selectively inhibits IL-23, achieved clinical response superior to that achieved with ustekinumab, an IL-12 and IL-23 inhibitor.
Psoriasis is a chronic immune-mediated inflammatory skin disease that occurs in 2% of adults; it has a substantial effect on quality of life and is associated with obesity, hypertension, diabetes mellitus, hypercholesterolemia, and the metabolic syndrome.
1
–
4
The proinflammatory cytokine interleukin-23 is thought to play a pivotal role in the pathogenesis of psoriasis by inducing and maintaining T helper (Th) 17 cells, Th22 cells, innate lymphoid cells, and the effector cytokines interleukin-17, interleukin-22, and tumor necrosis factor (TNF) α.
5
–
9
Interleukin-23 is composed of two subunits, p19 and p40. The p19 subunit is unique to interleukin-23, whereas the p40 subunit . . .</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Basal cell carcinoma</subject><subject>Body weight</subject><subject>Carcinoma</subject><subject>Cytokines</subject><subject>Dermatologic Agents - adverse effects</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Drug dosages</subject><subject>FDA approval</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin G</subject><subject>Immunotherapy</subject><subject>Interleukin 12</subject><subject>Interleukin 23</subject><subject>Interleukin-12 - antagonists & inhibitors</subject><subject>Interleukin-23 - antagonists & inhibitors</subject><subject>Kaplan-Meier Estimate</subject><subject>Light therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Pharmaceutical industry</subject><subject>Psoriasis</subject><subject>Psoriasis - classification</subject><subject>Psoriasis - drug therapy</subject><subject>Scalp - pathology</subject><subject>Severity of Illness Index</subject><subject>Skin</subject><subject>Skin cancer</subject><subject>TNF inhibitors</subject><subject>Tumor necrosis factor-TNF</subject><subject>Ustekinumab - adverse effects</subject><subject>Ustekinumab - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10E1Lw0AQBuBFFFurR68SEMHL6n4ne5RSq9KqqD2HTTKBtE227iaC_nq3tgoKzmVgeHgZXoSOKbmgRKrL-9Hd1BqqSExovIP6VHKOhSBqF_UJYQkWseY9dOD9nIShQu-jHksE45zQPho_Vd40i-qjq00WvYHznY9mvoVF1XydSuuiqS3AmRZwa_EzBATR49K8dmF56yrjK3-I9kqz9HC03QM0ux69DG_w5GF8O7ya4Jxr0uKcZTxWMclEwUtZslInUhSUSUYZV9QkHIoClKYCaC6VYjITccaMLoHHoDgfoPNN7srZ8IBv07ryOSyXpgHb-ZQmmpJEJ0IGevqHzm3nmvDdWhHGhVQkKLxRubPeOyjTlatq495TStJ1w-mvhoM_2aZ2WQ3Fj_6uNICzDahrnzYwr_8J-gS-oIBZ</recordid><startdate>20170420</startdate><enddate>20170420</enddate><creator>Papp, Kim A</creator><creator>Blauvelt, Andrew</creator><creator>Bukhalo, Michael</creator><creator>Gooderham, Melinda</creator><creator>Krueger, James</creator><creator>Lacour, Jean-Philippe</creator><creator>Menter, Alan</creator><creator>Philipp, Sandra</creator><creator>Sofen, Howard</creator><creator>Tyring, Stephen</creator><creator>Berner, Beate R</creator><creator>Visvanathan, Sudha</creator><creator>Pamulapati, Chandrasena</creator><creator>Bennett, Nathan</creator><creator>Flack, Mary</creator><creator>Scholl, Paul</creator><creator>Padula, Steven J</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20170420</creationdate><title>Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis</title><author>Papp, Kim A ; Blauvelt, Andrew ; Bukhalo, Michael ; Gooderham, Melinda ; Krueger, James ; Lacour, Jean-Philippe ; Menter, Alan ; Philipp, Sandra ; Sofen, Howard ; Tyring, Stephen ; Berner, Beate R ; Visvanathan, Sudha ; Pamulapati, Chandrasena ; Bennett, Nathan ; Flack, Mary ; Scholl, Paul ; Padula, Steven J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-c2b37670b4d3f5f2f9854d125212361a83edde6914e1c56625b47b2a9fe37e633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Basal cell carcinoma</topic><topic>Body weight</topic><topic>Carcinoma</topic><topic>Cytokines</topic><topic>Dermatologic Agents - adverse effects</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Drug dosages</topic><topic>FDA approval</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin G</topic><topic>Immunotherapy</topic><topic>Interleukin 12</topic><topic>Interleukin 23</topic><topic>Interleukin-12 - antagonists & inhibitors</topic><topic>Interleukin-23 - antagonists & inhibitors</topic><topic>Kaplan-Meier Estimate</topic><topic>Light therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Pharmaceutical industry</topic><topic>Psoriasis</topic><topic>Psoriasis - classification</topic><topic>Psoriasis - drug therapy</topic><topic>Scalp - pathology</topic><topic>Severity of Illness Index</topic><topic>Skin</topic><topic>Skin cancer</topic><topic>TNF inhibitors</topic><topic>Tumor necrosis factor-TNF</topic><topic>Ustekinumab - adverse effects</topic><topic>Ustekinumab - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Papp, Kim A</creatorcontrib><creatorcontrib>Blauvelt, Andrew</creatorcontrib><creatorcontrib>Bukhalo, Michael</creatorcontrib><creatorcontrib>Gooderham, Melinda</creatorcontrib><creatorcontrib>Krueger, James</creatorcontrib><creatorcontrib>Lacour, Jean-Philippe</creatorcontrib><creatorcontrib>Menter, Alan</creatorcontrib><creatorcontrib>Philipp, Sandra</creatorcontrib><creatorcontrib>Sofen, Howard</creatorcontrib><creatorcontrib>Tyring, Stephen</creatorcontrib><creatorcontrib>Berner, Beate R</creatorcontrib><creatorcontrib>Visvanathan, Sudha</creatorcontrib><creatorcontrib>Pamulapati, Chandrasena</creatorcontrib><creatorcontrib>Bennett, Nathan</creatorcontrib><creatorcontrib>Flack, Mary</creatorcontrib><creatorcontrib>Scholl, Paul</creatorcontrib><creatorcontrib>Padula, Steven J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>New England Journal of Medicine</collection><collection>Biological Sciences</collection><collection>ProQuest Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Psychology</collection><collection>ProQuest Research Library</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Papp, Kim A</au><au>Blauvelt, Andrew</au><au>Bukhalo, Michael</au><au>Gooderham, Melinda</au><au>Krueger, James</au><au>Lacour, Jean-Philippe</au><au>Menter, Alan</au><au>Philipp, Sandra</au><au>Sofen, Howard</au><au>Tyring, Stephen</au><au>Berner, Beate R</au><au>Visvanathan, Sudha</au><au>Pamulapati, Chandrasena</au><au>Bennett, Nathan</au><au>Flack, Mary</au><au>Scholl, Paul</au><au>Padula, Steven J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2017-04-20</date><risdate>2017</risdate><volume>376</volume><issue>16</issue><spage>1551</spage><epage>1560</epage><pages>1551-1560</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>In a phase 2 trial involving 166 patients with moderate-to-severe plaque psoriasis, risankizumab, a humanized monoclonal antibody that selectively inhibits IL-23, achieved clinical response superior to that achieved with ustekinumab, an IL-12 and IL-23 inhibitor.
Psoriasis is a chronic immune-mediated inflammatory skin disease that occurs in 2% of adults; it has a substantial effect on quality of life and is associated with obesity, hypertension, diabetes mellitus, hypercholesterolemia, and the metabolic syndrome.
1
–
4
The proinflammatory cytokine interleukin-23 is thought to play a pivotal role in the pathogenesis of psoriasis by inducing and maintaining T helper (Th) 17 cells, Th22 cells, innate lymphoid cells, and the effector cytokines interleukin-17, interleukin-22, and tumor necrosis factor (TNF) α.
5
–
9
Interleukin-23 is composed of two subunits, p19 and p40. The p19 subunit is unique to interleukin-23, whereas the p40 subunit . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>28423301</pmid><doi>10.1056/NEJMoa1607017</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2017-04, Vol.376 (16), p.1551-1560 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1891089845 |
| source | MEDLINE; Free E-Journal (出版社公開部分のみ）; New England Journal of Medicine |
| subjects | Adult Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Basal cell carcinoma Body weight Carcinoma Cytokines Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use Double-Blind Method Drug dosages FDA approval Female Humans Immunoglobulin G Immunotherapy Interleukin 12 Interleukin 23 Interleukin-12 - antagonists & inhibitors Interleukin-23 - antagonists & inhibitors Kaplan-Meier Estimate Light therapy Male Middle Aged Monoclonal antibodies Pharmaceutical industry Psoriasis Psoriasis - classification Psoriasis - drug therapy Scalp - pathology Severity of Illness Index Skin Skin cancer TNF inhibitors Tumor necrosis factor-TNF Ustekinumab - adverse effects Ustekinumab - therapeutic use |
| title | Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T06%3A34%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risankizumab%20versus%20Ustekinumab%20for%20Moderate-to-Severe%20Plaque%20Psoriasis&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Papp,%20Kim%20A&rft.date=2017-04-20&rft.volume=376&rft.issue=16&rft.spage=1551&rft.epage=1560&rft.pages=1551-1560&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa1607017&rft_dat=%3Cproquest_cross%3E4321886127%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1890234560&rft_id=info:pmid/28423301&rfr_iscdi=true |